Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-7904L vs 5-FU/leucovorin in first-line biliary tract cancer
2004-001155-11Phase 2Completed
- Sponsor
- OSI Pharmaceuticals, Inc.
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OSI-7904L in cholangiocarcinoma (CCA) (2 arms), sponsored by OSI Pharmaceuticals, Inc. Primary endpoint: Objective tumor response rate. Started Dec 2005; status: completed.
02
Drugs
OSI-7904L
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2004-001155-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001155-11.